All News

Giants,women,rheumatology

ICYMI: 25 Great Women in Rheumatology

d Jack Cush, MD

I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? This was prompted by a smart article in Annals of Rheumatic Disease written by Drs. Tuhina Neogi (Boston) and Nicola Dalbeth (N. Zealand), entitled "Where are the women ‘Heroes and Pillars of Rheumatology’?

Read Article
joint.wrist_.pain_.CTS_.Carpal.jpg

ICYMI: Carpal Tunnel - Steroid injection vs. Night Splinting

d Jack Cush, MD

A prospective, pragmatic, open-label, randomized trial conducted by the UK National Health Service, studied interventions in patients with carpal tunnel syndrome (CTS) and found no advantage to either CTS corticosteroid injection (CSI) or night splinting (NS) as the initial treatment of CTS.

Read Article
ANA.Wikipedia.jpg (keep)

ICYMI: New Laboratory Insights for the ANA+ Consult

d Jack Cush, MD

A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).

Read Article
alcohol%20glasses-919071__180.jpg (keep)

ICYMI: RA Disease Activity and Alcohol Use

d Jack Cush, MD

Despite its well known toxicities, alcohol is known to be antiinflammatory. The effects of alcohol use in rheumatoid arthritis (RA) is less known, but a recent study suggests that alcohol consumption was dose-dependently associated with lower disease activity and higher health-related quality of life in RA patients.

Read Article
RT @synovialjoints :The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

RT @synovialjoints : The course of symptoms in CSA to RA showed greater severity in the ACPA+ group compared to the ACPA- group. This correlated with MRI-subclinical joint score, suggesting different underlying processes Khidir S Abst#POS319 #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

RT @synovialjoints : The International Map of AxSpA (IMAS) of &gt;5k patients: delay mean 7.4+/-9 years, 75% active disease, 60% poor mental health, 21% sick leave, 4.6 GP visits before diagnosis, fear=disease progression, hope=relief of pain, IMAS Abst#POS0298 #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

RT @synovialjoints : The definition of early axSpA based on expert consensus after going through the Delphi process by ASAS is that the duration of axial symptoms is equal or less than 2 years. Navarro-Compan V, Abst#OP0055 #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

RT @Janetbirdope : #Top #EULAR learnings #SLE #recommendations 1 Limit #prednisone 2 use #biologics early if poor prognosis 3 #lupus #nephritis - treat early with #belimumab or #voclosporin and more Rx in #RCTs #gamechanger

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of 62 RCTs, 16 LTEs, 82 366 Pt-Yrs JAK exposure. JAKi malignancy incid rate = 1.15/100 PYs in RCTs (1.26/100PYs overall). Network meta-analyses show no diff betw JAK &amp; PBO or MTX in NMSC, but signif increased malignancy risk (IRR 1.50) https://t.co/ANa7zYmhPx

Links:

Dr. John Cush RheumNow ( View Tweet)

JAK inhibitors have been effective in refractory inflammatory myositis, all open label, but no controlled trials. #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

Treatment of IIM, MTX or AZA or IVIG are 1st line (with steroids). #EULAR2023 https://t.co/0B1zzeqm1L

Links:

Dr. John Cush RheumNow ( View Tweet)

Check SSc-ILD Patients on Nintedinib for Malnutrition During nintedanib treatment for interstitial lung disease associated with SSc-ILD, clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested. https://t.co/TmN71qSCb2 https://t.co/TVU2qcPdZE

Links:

Dr. John Cush RheumNow ( View Tweet)
2022 of fibromyalgia Year in review discusses possible causes (inflammation, gut dysbiosis, neuroinflammation), new Rx (kinin antagonists, neurostimulation, mind-body Rx; but more needed on ketamine, vitamin D, and hormonal therapy https://t.co/sya8fSCbFX https://t.co/F2HDcp2XYb

Links:

Dr. John Cush RheumNow ( View Tweet)
Paradoxical PsO (PP) studied in 2867 RA & 5316 SpA pts. 136 (1.7%) had paradox. Rxn, median 12 mos post TNFi [pustular (60%) or palmoplantar (31%)]. 73% PP favorably switched to other TNFi 46% or non-TNFi 27%. RA PP took SSZ, HCQ, LEF; SpA PP more smokers https://t.co/w1EQEvHbeG https://t.co/aAwKxdNYk1

Links:

Dr. John Cush RheumNow ( View Tweet)
Paradoxical Psoriasis in Kids Taking TNF Inhibitors A multicenter cohort study reported a large cohort of pediatric patients receiving TNF inhibitor therapy complicated by psoriasis, regardless of treatment indication or the specific TNF inhibitor. https://t.co/9WxkAt8NnS https://t.co/sGvb1eZWE0

Links:

Dr. John Cush RheumNow ( View Tweet)
TitAIN Study: Secukinumab Efficacy in Giant Cell Arteritis A phase 2 trial has demonstrated the efficacy of secukinumab, an anti-interleukin-17A monoclonal antibody, in patients with active giant cell arteritis (GCA). https://t.co/rmYBXBV3RP https://t.co/q1CfhuGSj7

Links:

Dr. John Cush RheumNow ( View Tweet)
Belimumab in adult inflamm myositis (IIM)? Small study 15 IIM pts recv ≥ 5 doses of belimumab or placebo; Treatment success (TIS ≥ 40) was more common with BEL (55% vs 33%) as was defined improvement (DOI: 33% vs 17%); not signif, but interesting! https://t.co/3xL0ylJbcs https://t.co/Oerf0yI4Jg

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved a 2nd JAK inhibitor for Alopecia areata - Pfizers Ritlecitinib (Litfulo) is approved for Adults and Adolescents (>12 yrs) With Severe Alopecia Areata (based on ALLEGRO trial, pub in Lancet) https://t.co/Uods58glJG https://t.co/Uods58glJG https://t.co/syCqnG6sLg

Links:

Dr. John Cush RheumNow ( View Tweet)
PRE-CLINICAL RA: What do you need to better manage pre-clinical (at-risk) Rheumatoid arthritis Patients? Rheumatologists vote here >>https://t.co/lt38vJMEIA

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×